ProQR Therapeutics (NASDAQ:PRQR) Receives Average Rating of “Buy” from Brokerages

Shares of ProQR Therapeutics (NASDAQ:PRQR) have been given an average recommendation of “Buy” by the six ratings firms that are presently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $8.83.

A number of research analysts have commented on PRQR shares. StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their price target for the company from $6.00 to $14.00 in a research note on Tuesday, October 29th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Chardan Capital reissued a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Finally, Oppenheimer assumed coverage on shares of ProQR Therapeutics in a report on Friday. They set an “outperform” rating and a $15.00 price target on the stock.

ProQR Therapeutics Stock Down 7.6 %

PRQR stock opened at $2.42 on Monday. The company has a 50 day moving average of $3.23 and a two-hundred day moving average of $2.51. The company has a market cap of $197.67 million, a price-to-earnings ratio of -7.56 and a beta of 0.30. ProQR Therapeutics has a 12-month low of $1.61 and a 12-month high of $4.62.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Privium Fund Management B.V. raised its stake in shares of ProQR Therapeutics by 0.9% in the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after purchasing an additional 51,663 shares in the last quarter. OneDigital Investment Advisors LLC increased its holdings in ProQR Therapeutics by 37.0% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 15,550 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in shares of ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 7,300 shares in the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).